POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY - Leng, X.; Leszczynski, P.; Jeka, S.; Liu, S.; Liu, H.; Miakisz, M.; Gu, J.; Kilasonia, L.; Stanislavchuk, M.; Yang, X.; Zhou, Y.; Dong, Q.; et al. (Annals of the rheumatic diseases, 2022)